Our Director of Research Dr Sheona Scales describes her four highlights from this year's Clinical Trials on Alzheimer's ...

Alzheimer’s trials face the unique challenge of studying participants with cognitive decline, amid a move towards digital ...

Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October ...

Donanemab became the second Alzheimer's drug that targets causative deposited plaque in the brain to win the coverage after ...

Tokyo, Nov. 13 (Jiji Press)--Japan's Central Social Insurance Medical Council, which advises the health minister, approved Wednesday public health insurance coverage for donanemab, an Alzheimer's ...

I am proposing that all companies currently engaged in developing biosimilars join hands with their regulatory and scientific ...

Today, the first monoclonal antibodies, lecanemab and donanemab, are available, showing that their reduction effect on these ...

The $74.5 million grant will fund a study focused on an inherited genetic mutation that has been linked to Alzheimer's.

A single course of newly approved Alzheimer's drug donanemab-azbt, the second medicine available in Japan targeting proteins in the brains of sufferers of the debilitating disease, will cost 3.08 ...